Cargando…
Hsp90 (Heat Shock Protein 90) Inhibitor Occupancy Is a Direct Determinant of Client Protein Degradation and Tumor Growth Arrest in Vivo
Several Hsp90 (heat shock protein 90) inhibitors are currently under clinical evaluation as anticancer agents. However, the correlation between the duration and magnitude of Hsp90 inhibition and the downstream effects on client protein degradation and cancer cell growth inhibition has not been thoro...
Autores principales: | Tillotson, Bonnie, Slocum, Kelly, Coco, John, Whitebread, Nigel, Thomas, Brian, West, Kip A., MacDougall, John, Ge, Jie, Ali, Janid A., Palombella, Vito J., Normant, Emmanuel, Adams, Julian, Fritz, Christian C. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000965/ https://www.ncbi.nlm.nih.gov/pubmed/20940293 http://dx.doi.org/10.1074/jbc.M110.141580 |
Ejemplares similares
-
HSP90 Inhibition Enhances Antimitotic Drug-Induced Mitotic Arrest and Cell Death in Preclinical Models of Non-Small Cell Lung Cancer
por: O'Connell, Brenda C., et al.
Publicado: (2014) -
Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery
por: Li, Ting, et al.
Publicado: (2018) -
Immunotherapeutic targeting of HSP90 client proteins in BRAF-inhibitor resistant melanoma
por: Fecek, Ronald J, et al.
Publicado: (2015) -
SUV39H1 is a New Client Protein of Hsp90 Degradated by Chaetocin as a Novel C-Terminal Inhibitor of Hsp90
por: Lian, Bin, et al.
Publicado: (2021) -
HECTD3 Mediates an HSP90-Dependent Degradation Pathway for Protein Kinase Clients
por: Li, Zhaobo, et al.
Publicado: (2017)